Combination of trastuzumab and vinorelbine in metastatic breast cancer

Japanese Journal of Clinical Oncology

Volumn 33, Issue 10, 2003, Pages 514-517

  Suzuki, Yasuhiro ^a   Tokuda, Yutaka ^a,b   Saito, Yuki ^a   Ohta, Masatoshi ^a   Tajima, Tomoo ^a  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NONE   (Japan)

Author keywords

Breast cancer; HER2 neu; Trastuzumab; Vinorelbine

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MITOMYCIN C; NAVELBINE; PACLITAXEL; TRASTUZUMAB; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; MONOCLONAL ANTIBODY; VINBLASTINE;

ADULT; AGED; ANEMIA; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RELAPSE; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; GENE OVEREXPRESSION; HUMAN; INJECTION SITE REACTION; LEUKOPENIA; METASTASIS; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OUTPATIENT CARE; THROMBOCYTOPENIA; TREATMENT DURATION; VASCULITIS; VOMITING; BIOSYNTHESIS; BONE TUMOR; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; DRUG ADMINISTRATION; FEMALE; LIVER TUMOR; LUNG TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; BREAST NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; FATIGUE; FEMALE; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; MIDDLE AGED; NEUTROPENIA; RECEPTOR, ERBB-2; VASCULITIS; VINBLASTINE;

EID: 0642281050     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyg101     Document Type: Article

References (14)

1. Tokuda Y, Suzuki Y, Ohta M, Saito Y, Kubota M, Tajima T, et al. Compassionate use of humanized anti-HER2/neu protein, trastuzumab for metastatic breast cancer in Japan. Breast Cancer 2001;8:310-5.
2. Tokuda Y, Ohta M, Suzuki Y, Kubota M, Tajima T. Clinical development of trastuzumab in breast cancer. Breast Cancer 2001;8:93-7.
3. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344:783-92.
4. Seidman AD, Fornier MN, Esteva FJ, Tan L, Kaptain S, Bach A, et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 2001;19:2587-95.
5. Esteva FJ, Valero V, Booser D, Guerra LT, Murray JL, Pusztai L, et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20: 1800-8.
6. Pegram MD, Lopez A, Konecny G, Slamon DJ. Trastuzumab and chemotherapeutics: Drug interactions and synergies. Semin Oncol 2000;27:21-5; 92-100.
7. Burstein HJ, Kuter I, Campos SM, Gelman RS, Tribou L, Parker LM, et al. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 2001;19:2722-30.
8. Burstein HJ, Marcom PK, Lambert-Falls R, Halvin K, Overmoyer B, Friendlander RJ, et al. Multicenter phase II study of transtuzumab (Herceptin; H) and vinorelbine (Navelbine; N) as first-line therapy for HER2 overexpressing metastatic breast cancer (HER2+MBC) [abstract 211]. Proc ASCO 2002;21:53a.
9. Trotti A, Byhardt R, Stetz J, Gwde C, Corn B, Fu K, et al. Related Articles, Link Common toxicity criteria: Version 2.0. an improved reference for grading the acute effects of cancer treatment: Impact on radiotherapy. Int J Radiat Oncol Biol Phys 2000;47:13-47.
10. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-26.
11. Mangoney P, Andriamialisoa RZ, Lallemand JY, Langlois N, Langlois Y, Potier P. 5′ - Nor anhydrovinblastine. Prototype of a new class of vinblastine derivatives. Tetrahedron 1979;35:2175-9.
12. Fellous A, Ohayan R, Vacassin T, Binet S, Lataste H, Krikorian A, et al. Biochemical effect of Navelbine on tubulin and associated protein. Semin Oncol 1989;16(Suppl 4):9-14.
13. Fumoleou P, Delgado FM, Delozier T, Monnier A, Gil Delgado MA, Kerbrat P, et al. Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 1993;11:1245-52.
14. Weber BL, Vogel C, Jones S, Harvey H, Hutchins L, Bigley J, et al. Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer. J Clin Oncol 1995;13:2722-30.